Jove
Visualize
Contact Us

Related Experiment Videos

Cellular immune responses against hepatitis C virus.

Margaret James Koziel1

  • 1Infectious Disease Division, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, MA 02215, USA. mkoziel@bidmc.harvard.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|November 3, 2005
PubMed
Summary

Cellular immune responses are crucial for controlling hepatitis C virus (HCV) infection progression and liver disease, even if they don't clear the virus. Understanding HIV coinfection's impact on these responses is key to treating liver disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet (London, England)·2026
Same author

Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study.

EClinicalMedicine·2023
Same author

Predictors of treatment for hepatitis C virus (HCV) infection in drug users.

Substance abuse·2008
Same author

Translational research in liver disease.

Hepatology (Baltimore, Md.)·2008
Same author

Immune responses during acute and chronic infection with hepatitis C virus.

Clinical immunology (Orlando, Fla.)·2008
Same author

HIV and liver disease forum: conference proceedings.

Hepatology (Baltimore, Md.)·2007
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Immunology
  • Hepatology
  • Virology

Background:

  • Cellular immune responses, including CD4+ and CD8+ T cells, are vital for clearing acute hepatitis C virus (HCV) infections.
  • The role of cellular immunity in chronic HCV infection and liver disease progression remains unclear.
  • Existing models suggest cellular immunity exacerbates liver injury, but clinical data indicate immune dysfunction accelerates disease.

Purpose of the Study:

  • To investigate the role of cellular immune responses in the progression of liver disease during chronic hepatitis C virus (HCV) infection.
  • To explore the impact of human immunodeficiency virus (HIV) coinfection on cellular immune responses to HCV.
  • To elucidate the mechanisms underlying liver disease pathogenesis in both immunocompromised and immunocompetent hosts.

Main Methods:

Related Experiment Videos

  • Review of existing literature on cellular immune responses in acute and chronic hepatitis C.
  • Analysis of clinical data from patients with and without HIV coinfection.
  • Examination of proposed models of immune-mediated liver injury and disease progression.

Main Results:

  • Clinical evidence suggests that cellular immune dysfunction, as seen in HIV coinfection, correlates with more rapid liver disease progression in chronic HCV.
  • Recent findings indicate that cellular immune responses can limit liver disease progression, despite their inability to achieve viral clearance.
  • Limited data exist on how HIV coinfection specifically modulates the cellular immune response to HCV.

Conclusions:

  • Cellular immune responses play a protective role in limiting liver disease progression in chronic HCV infection.
  • Further research into HIV-HCV coinfection is needed to understand the interplay of immune responses and liver disease pathogenesis.
  • Findings may inform therapeutic strategies for liver disease in diverse patient populations.